If You Invested in MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company focused on inflammatory skin and joint diseases. The company is advancing sonelokimab (SLK, M1095), a novel investigational Nanobody® that targets interleukin-17A and interleukin-17F (IL‑17A and IL‑17F) dimers that drive inflammation. MoonLake describes its mission as unlocking the potential of sonelokimab to improve outcomes in conditions with substantial unmet medical need, particularly in dermatology and rheumatology.

According to company disclosures, sonelokimab is a humanized Nanobody of approximately 40 kDa consisting of three VHH (variable regions of heavy-chain-only antibodies) domains linked by flexible glycine–serine spacers. Two domains bind IL‑17A and IL‑17F with high affinity, inhibiting the IL‑17A/A, IL‑17A/F and IL‑17F/F dimers, while a third domain binds human albumin to facilitate enrichment at sites of inflammatory edema. This molecular design is central to MoonLake’s development strategy across multiple inflammatory indications.

Core focus areas and indications

MoonLake states that its lead development programs for sonelokimab are in:

• Hidradenitis suppurativa (HS) – a chronic, debilitating inflammatory skin disease characterized by painful lesions and irreversible tissue destruction. HS is a major focus, with adult and adolescent clinical programs.
• Psoriatic arthritis (PsA) – a chronic inflammatory joint and skin disease with multiple clinical domains.
• Axial spondyloarthritis (axSpA) – an inflammatory condition affecting the axial skeleton, under evaluation in Phase 2 trials.
• Palmoplantar pustulosis (PPP) – a debilitating inflammatory skin condition affecting palms and soles, evaluated in the Phase 2 LEDA trial.

MoonLake also cites prior and ongoing work in plaque-type psoriasis through third-party Phase 1 and Phase 2b trials of sonelokimab, where high-threshold clinical responses and reductions in pro-inflammatory gene expression were observed.

Clinical development programs

In HS, MoonLake is running the Phase 3 VELA program, comprising two global, randomized, double-blind, placebo-controlled trials (VELA‑1 and VELA‑2) in adults with moderate-to-severe HS. Both trials use the higher clinical response threshold of HiSCR75 (Hidradenitis Suppurativa Clinical Response 75) as the primary endpoint, defined as at least a 75% reduction in abscess and inflammatory nodule count with no increase in abscess or draining tunnel count. The VELA trials also assess secondary endpoints such as HiSCR50, changes in the International HS Severity Score System (IHS4), Dermatology Life Quality Index (DLQI), pain scores, and draining tunnel resolution.

Week 16 results from VELA‑1 and VELA‑2, analyzed using both composite and treatment policy strategies, showed that sonelokimab achieved statistically significant and clinically meaningful improvements across primary and key secondary endpoints in the combined program, with a favorable safety profile and no new safety signals reported. The company reports that all patients receive sonelokimab 120 mg from week 16 to week 48, with a final assessment at week 52 and an open-label extension planned for up to two years.

In addition, MoonLake is conducting VELA‑TEEN, an open-label, single-arm Phase 3 trial of sonelokimab in adolescents (ages 12–17) with moderate-to-severe HS. The primary phase is 24 weeks, focusing on pharmacokinetics, safety, and tolerability, with secondary endpoints including HiSCR75, HiSCR50, IHS4 changes, and pediatric quality-of-life and pain measures.

Psoriatic arthritis and axial spondyloarthritis

For PsA, MoonLake has initiated the Phase 3 IZAR program, consisting of two global, randomized, double-blind, placebo-controlled trials:

• IZAR‑1 – enrolling biologic-naïve adults with active PsA and including evaluation of radiographic progression.
• IZAR‑2 – enrolling adults with an inadequate response to tumor necrosis factor‑α inhibitors (TNF‑IR) and including risankizumab, an IL‑23 inhibitor, as an active reference arm.

Both IZAR trials are designed for 52 weeks of treatment and use American College of Rheumatology 50 (ACR50) response at week 16 as the primary endpoint, with multiple secondary endpoints covering joint, skin, nail, multidomain outcomes and patient-reported measures. The IZAR design is informed by the global Phase 2 ARGO trial in PsA, where MoonLake reports that sonelokimab produced significant improvements across key outcomes, including high proportions of patients achieving ACR50 and Minimal Disease Activity at week 24, with a safety profile consistent with previous studies.

In axial spondyloarthritis, MoonLake is conducting the Phase 2 S‑OLARIS trial in active axSpA. The company notes that S‑OLARIS and the related P‑OLARIS trial in PsA incorporate trial designs that complement traditional clinical outcomes with cellular imaging techniques.

Palmoplantar pustulosis and other dermatologic indications

The Phase 2 LEDA trial evaluates sonelokimab 120 mg administered subcutaneously in adults with PPP. The primary endpoint is percent change from baseline in the Palmoplantar Psoriasis Area and Severity Index (PPPASI), with secondary endpoints including PPPASI75 (at least 75% improvement). MoonLake reports that LEDA includes a translational research component using peripheral blood and tissue biomarkers, and that interim and later results have shown clinically meaningful and statistically significant benefit with a safety profile consistent with previous sonelokimab trials.

Sonelokimab has also been evaluated in plaque-type psoriasis in a randomized, placebo-controlled third-party Phase 2b trial and an earlier Phase 1 trial. These studies showed high-threshold clinical responses (e.g., Investigator’s Global Assessment 0/1 and PASI 90/100) and normalization of cutaneous pro-inflammatory gene expression, with tolerability similar to an active control.

Regulatory and strategic positioning

MoonLake has reported positive regulatory interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including end-of-Phase 2 feedback supporting the Phase 3 VELA and IZAR programs. In a Type B meeting with the FDA focused on HS, the agency indicated that MoonLake may establish substantial evidence of effectiveness for sonelokimab in HS without additional HS clinical trials, based on data from the MIRA, VELA‑1 and VELA‑2 trials, and advised inclusion of VELA‑2 data to inform safety in a planned Biologics License Application (BLA).

MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. The company is incorporated in the Cayman Islands and lists its Class A ordinary shares on Nasdaq under the symbol MLTX. It describes itself as a clinical-stage biopharmaceutical company with multiple ongoing Phase 2 and Phase 3 trials and a pipeline centered on sonelokimab in HS, PsA, axSpA, PPP and related inflammatory conditions.

Business model and financing

As a clinical-stage biopharmaceutical company, MoonLake’s activities are concentrated on research and development, clinical trial execution, regulatory interactions and preparation for potential commercialization of sonelokimab. The company has disclosed several financing steps to support these activities, including an underwritten offering of Class A ordinary shares and a non-dilutive term loan facility with Hercules Capital. MoonLake’s SEC filings and press releases state that these resources are intended to fund clinical development of sonelokimab, preparations for potential product launch, and general corporate purposes.

Nanobody® technology

MoonLake emphasizes that Nanobodies® are antibody-derived targeted therapies based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). According to the company, Nanobodies may offer advantages such as small size, enhanced tissue penetration, resistance to temperature changes, manufacturing characteristics, and the ability to be designed into multivalent molecules with tailored target combinations. Sonelokimab is presented as an example of this platform applied to IL‑17A/IL‑17F–mediated inflammatory disease.

Key points for MLTX stock watchers

• Ticker and exchange: MoonLake Immunotherapeutics trades on Nasdaq under the symbol MLTX.
• Stage: Clinical-stage, with multiple Phase 3 and Phase 2 programs rather than approved commercial products.
• Lead asset: Sonelokimab, an investigational Nanobody targeting IL‑17A and IL‑17F dimers, in HS, PsA, axSpA, PPP and related indications.
• Geographic base: Headquartered in Zug, Switzerland; incorporated in the Cayman Islands.

FAQs